Invivyd, Inc.
IVVD- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001832038
No open-market purchases or sales by Invivyd, Inc. insiders were filed in the last 90 days; 125 institutions reported holding it in 13F filings for Q2 2026, worth $203.1M in total; Maverick Capital is the only superinvestor holding it.
Key figures
- Market capClose on Nov 17, 2026
- $151.5M
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, −11 vs. previous quarter
- 125
- 13F valueReported value at the end of Q2 2026
- $203.1M
- Superinvestors holdingAt the end of Q2 2026
- 1
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2025
- $53.4M
- +110.5% year over year
- Net income, FY2025
- -$52.5M
- No comparable prior period
- Free cash flow, FY2025
- -$58.3M
- No comparable prior period
- Revenue, Q3 FY2026
- $15.4M
- +17.7% year over year
Revenue flow, FY2025
Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.
Net loss for FY2025: $52.5M (98.2% of revenue).
Short interest
See short dataFrom FINRA, settlement date Oct 30, 2026.
- Short interest
- 36.2M
- Shares sold short
- Change
- −842.1K
- −2.3% vs. previous
- Days to cover
- 9.66
- At average daily volume
Superinvestors holding IVVD, Q2 2026
Go to the superinvestors tab1 superinvestor reports holding Invivyd, Inc. on Form 13F. Percentages are the stock's share of each portfolio.
Latest insider trades
See all insider tradesOpen-market purchases and sales by Invivyd, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Aug 18, 2026 (view filing)8:10 PM ET | Aug 17-18 | 1 day | Lee Timothy EdwardChief Commercial Officer | SSale | −40.8K | $0.7766 | −$31.7K | −18.6%178.9K after | 2 lots10b5-1 |
| Aug 18, 2026 (view filing)8:10 PM ET | Aug 17-18 | 1 day | Green JulieChief Human Resources Officer | SSale | −40.8K | $0.7766 | −$31.7K | −19.4%168.9K after | 2 lots10b5-1 |
| Aug 18, 2026 (view filing)8:10 PM ET | Aug 17-18 | 1 day | Duke William E.Chief Financial Officer | SSale | −40.8K | $0.7766 | −$31.7K | −19.4%168.9K after | 2 lots10b5-1 |
| Aug 18, 2026 (view filing)8:10 PM ET | Aug 17-18 | 1 day | Andersen JillChief Legal Officer, Secretary | SSale | −68.0K | $0.7766 | −$52.8K | −19.3%283.8K after | 2 lots10b5-1 |
| Aug 18, 2026 (view filing)8:10 PM ET | Aug 17-18 | 1 day | Allen Robert D. IIIChief Scientific Officer | SSale | −37.7K | $0.7766 | −$29.3K | −17.4%178.8K after | 2 lots10b5-1 |
| Feb 18, 2026 (view filing) | Feb 17-18 | 1 day | Allen Robert D. IIIChief Scientific Officer | SSale | −37.6K | $1.56 | −$58.7K | −24.7%114.5K after | 2 lots10b5-1 |
| Feb 18, 2026 (view filing) | Feb 17-18 | 1 day | Green JulieChief Human Resources Officer | SSale | −40.6K | $1.56 | −$63.4K | −27.4%107.7K after | 2 lots10b5-1 |
| Feb 18, 2026 (view filing) | Feb 17-18 | 1 day | Duke William E.Chief Financial Officer | SSale | −40.6K | $1.56 | −$63.4K | −27.4%107.7K after | 2 lots10b5-1 |
| Feb 18, 2026 (view filing) | Feb 17-18 | 1 day | Lee Timothy EdwardChief Commercial Officer | SSale | −40.6K | $1.56 | −$63.4K | −25.7%117.7K after | 2 lots10b5-1 |
| Feb 18, 2026 (view filing) | Feb 17-18 | 1 day | Andersen JillChief Legal Officer, Secretary | SSale | −67.7K | $1.56 | −$105.7K | −27.1%181.7K after | 2 lots10b5-1 |
Top 10 13F holders, Q2 2026
See all 125 holdersThe largest institutional positions in Invivyd, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Jupiter Topco LLC | 34,173,104 | $30.0M | 0.01% | +34,173,104 | New |
| BVF Inc | 28,165,000 | $24.6M | 0.63% | +8,640,000+44.3% | Added |
| Maverick Capital LtdSuperinvestorMaverick Capital | 18,970,913 | $16.6M | 0.15% | 00.0% | Unchanged |
| Perceptive Advisors LLC | 18,490,636 | $16.1M | 0.25% | −2,368,667−11.4% | Reduced |
| BlackRock, Inc. | 16,134,885 | $14.1M | 0.00% | +11,853,095+276.8% | Added |
| Vanguard Capital Management LLC | 10,496,507 | $9.15M | 0.00% | +422,181+4.2% | Added |
| M28 Capital Management LP | 9,248,250 | $8.07M | 17.11% | 00.0% | Unchanged |
| Saturn V Capital Management LLC | 8,392,288 | $7.32M | 1.05% | −2,556,796−23.4% | Reduced |
| Soleus Capital Management, L.P. | 7,708,727 | $6.73M | 0.23% | 00.0% | Unchanged |
| Point72 Asset Management, L.P. | 7,542,061 | $6.58M | 0.01% | +7,498,130+17,068.0% | Added |
Holders of 5% or more of IVVD
See all 6 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of Invivyd, Inc..
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Janus Henderson Group PLC | 13G/A | 12.10%25.4M shares | +0.50 ppfrom 11.60% | Sep 8, 20252 filings | Nov 14, 2025 | SEC |
| Biotechnology Value Fund L P | 13G/A | 9.99%29.6M shares | +0.99 ppfrom 9.00% | Oct 22, 20253 filings | Aug 14, 2026 | SEC |
| Maverick Capital LtdSuperinvestorMaverick Capital | 13G/A | 8.30%24.4M shares | +1.60 ppfrom 6.70% | Feb 14, 20245 filings | Nov 16, 2026 | SEC |
| Adimab, LLC | 13D/A | 7.30%20.3M shares | −1.50 ppfrom 8.80% | Mar 30, 20226 filings | Dec 29, 2025 | SEC |
| Ra Capital Management, L.P. | 13G/A | 7.00%21.3M shares | −2.90 ppfrom 9.90% | Aug 29, 20253 filings | May 15, 2026 | SEC |